World Journal of Pharmaceutical Research
Molecular docking and admet study of coumarins exploring their potential as treatments for alzheimer 's disease
By *Devendra Kumar.
Abstract
Alzheimer's disease (AD) is a neurological illness that affects older individuals and manifests as memory loss, cognitive decline, and linguistic impairment. As per the cholinergic theory, AD is mostly associated with a drop in acetylcholine (AChE) levels in the brain due to damage to cholinergic neurons. Therefore, increasing AChE with acetylcholinesterase inhibition is one of the most effective ways to treat AD symptoms. Sonmez et al.[42] A class of physical and cognitive impairments known as neurodegenerative diseases are brought on by the death of brain neurons. The most prevalent ND, Alzheimer's disease has been diagnosed in over 30 million people worldwide. Its symptoms, which start with recurrent short-term memory loss and advance to the degradation of higher cognitive skills including language and decision-making, are progressive and permanent. The disease has a significant social and economic impact because of the nature of these symptoms. This neurodegeneration is the consequence of several interconnected pathways supported by genetic and environmental variables rather than a single cause or process. Treatment has become challenging because of this intricate pathophysiology, and the medications currently on the market mainly relieve symptoms. Mzezewa et al.[33] Alois Alzheimer, a German neuro scientist, told about the Alzheimer’s disease in 1907. One of his patients had cognitive impairment, behavioral issues, and memory loss. Deficiencies. A biopsy revealed significant brain damage, including ageing plaques, neuron muddle known as neurofibrillary Muddle and axis. lack of Nerve cell and synapses, primarily in the hippocampus and neocortex association regions. The Pathophysiology of Alzheimer's disease begins with hippocampal shrinkage About 80% of people 65 and older have Alzheimer's; dementia only affects a small percentage of people at this age, but the frequency of dementia in Alzheimer's rises to 25% in people 80 and older. In older adults, Alzheimer's disease (AD) is the most common cause of dementia., and it is typified by growing neurological changes. De et al.[12]






